在癌症患者中，去脂体重减少很常见，并且与更糟糕的结果相关，包括治疗耐受性和生存率降低。生物电阻抗分析（BIA）是一种流行的身体成分评估方法。我们评估了 BIA 衍生的身体成分参数在预测死亡率和剂量限制毒性 (DLT) 方面的价值。我们对患有实体肿瘤疾病并接受治疗的成年患者进行了一项前瞻性多中心 (n = 12) 观察性研究初步全身治疗。我们收集了 BIA 衍生参数的信息：相位角 (PhA) < 年龄和性别特定标准值的第 5 个百分位；标准化 PhA (SPA) <-1.65； Nutrigram® 对于男性和女性分别 <660 mg/24 h/m 和 <510 mg/24 h/m。主要结局和关键次要结局分别是 1 年死亡率和 DLT（需要延迟全身治疗或减少剂量的任何类型的严重毒性）。总共纳入 640 名患者。 12 个月时，286 名患者（47.6%）死亡。所有 BIA 衍生的身体成分参数均与死亡独立相关：SPA，风险比 (HR) = 1.59 [95% 置信区间 (CI) 1.30-1.95] (P < 0.001)； PhA，HR = 1.38（95% CI 1.13-1.69）（P = 0.002）； Nutrigram®，HR = 1.71 (95% CI 1.42-2.04) (P < 0.001)。 208 名患者 (32.5%) 发生了 DLT，身体成分参数与此结果相关，特别是 SPA：比值比 = 6.37 (95% CI 2.33-17.44) (P < 0.001)。研究证实，BIA 衍生的身体成分参数不仅与生存独立相关，而且与 DLT 独立相关。尽管我们的研究结果仅限于接受一线全身治疗的患者，但报告的证据可能对改善癌症患者的临床检查具有重要的实践意义。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

In patients with cancer, lean body mass loss is frequent and associated with worse outcomes, including reduced treatment tolerance and survival. Bioelectrical impedance analysis (BIA) is a popular method for body composition assessment. We evaluated the value of BIA-derived body composition parameters in predicting mortality and, for the first time, dose-limiting toxicity (DLT).We conducted a prospective multicenter (n = 12) observational study in adult patients with solid neoplastic disease and receiving primary systemic treatment. We collected information on BIA-derived parameters: phase angle (PhA) <5th percentile of age and gender-specific normative values; standardized PhA (SPA) <-1.65; Nutrigram® <660 mg/24 h/m and <510 mg/24 h/m for males and females, respectively. The primary outcome and the key secondary were 1-year mortality and DLT (any-type severe toxicity requiring a delay in systemic treatment administration or a reduction of its dosage), respectively.In total, 640 patients were included. At 12 months, death occurred in 286 patients (47.6%). All BIA-derived body composition parameters were independently associated with death: SPA, hazard ratio (HR) = 1.59 [95% confidence interval (CI) 1.30-1.95] (P < 0.001); PhA, HR = 1.38 (95% CI 1.13-1.69) (P = 0.002); Nutrigram®, HR = 1.71 (95% CI 1.42-2.04) (P < 0.001). DLT occurred in 208 patients (32.5%) and body composition parameters were associated with this outcome, particularly SPA: odds ratio = 6.37 (95% CI 2.33-17.44) (P < 0.001).The study confirmed that BIA-derived body composition parameters are independently associated not only with survival but also with DLT. Although our findings were limited to patients receiving first-line systemic treatment, the evidence reported may have important practice implications for the improvement of the clinical work-up of cancer patients.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.